Dissecting the origins of fetal hemoglobin modulation of sickle cell vaso-occlusion

剖析胎儿血红蛋白调节镰状细胞血管闭塞的起源

基本信息

  • 批准号:
    9258476
  • 负责人:
  • 金额:
    $ 19.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-10 至 2019-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION: Sickle cell disease (SCD) is a devastating hereditary disorder that affects more than 13 million people worldwide with health care costs in the U.S. alone exceeding $1 billion per year. The origin of SCD is the ability of a hemo- globin mutant (sickle hemoglobin or HbS) to polymerize into rigid fibers upon deoxygenation. These fibers reduce red blood cell deformability, which leads to large changes in blood rheology and can ultimately result in complete occlusion of the microvasculature, tissue infarction, organ damage, and even death. The only clinically approved therapeutic for SCD, hydroxyurea, is thought to work by inducing synthesis of fetal hemoglobin (HbF). HbF is known to inhibit HbS polymerization in vitro, but average HbF levels in blood correlate only weakly with patient outcomes, and hydroxyurea has widely variable clinical efficacy. Although new therapies have been proposed or are in development, the effect of these potential therapies on vaso-occlusion is difficult to predict without extensive trials in animal models and humans. Ultimately, the missing link is to understand the quantitative rela- tionship between cellular HbF levels and the likelihood of vaso-occlusion. This would allow us to predict the potential efficacy of new therapies and to clinically monitor patients who are receiving HbF inducing therapies such as hydroxyurea. In these studies, we will quantify the relationship between blood HbF levels and the risk of vaso-occlusion. Our primary hypothesis is that the therapeutic efficacy of HbF depends primarily on the distribu- tion of HbF among red blood cells (RBCs). If all RBCs contain more than a threshold percentage of HbF, patients are protected from vaso-occlusion, but having the majority of HbF segregated into only a few cells does not significantly improve patient outcomes. We propose to directly test this hypothesis using flow cytometry to quan- tify single RBC HbF distributions ("HbF heterocellularity"). We will correlate the HbF heterocellularity of patient blood with the risk of vaso-occlusion. Because vaso-occlusions are difficult to study or reproduce in vivo, we have developed a microfluidic platform to study vaso-occlusion in vitro. We will use this platform to quantify the likelihood of occlusion in a blood sample, and we will correlate this measurement with HbF heterocellularity measured from patient samples using quantitative flow cytometry. The result will be a clinical assay that can be used to monitor patien response to hydroxyurea and an assay for clinical trials of new therapies that induce HbF synthesis. Additionally, we anticipate that these studies will elucidate whether HbF is the primary therapeutic mechanism for hydroxyurea.
 产品说明:镰状细胞病(SCD)是一种毁灭性的遗传性疾病,影响全球1300多万人,仅在美国每年的医疗保健费用就超过10亿美元。SCD的起源是血红蛋白突变体(镰状血红蛋白或HbS)在脱氧时粘附成刚性纤维的能力。这些纤维降低了红细胞的变形能力,这导致血液流变学的巨大变化,并最终导致微血管的完全闭塞、组织梗死、器官损伤甚至死亡。临床上唯一批准的SCD治疗药物是羟基脲,被认为是通过诱导胎儿血红蛋白(HbF)的合成来起作用。已知HbF在体外抑制HbS聚合,但血液中的平均HbF水平与患者结果仅弱相关,并且羟基脲具有广泛可变的临床疗效。虽然已经提出或正在开发新的治疗方法,但如果没有在动物模型和人体中进行广泛的试验,这些潜在治疗方法对血管闭塞的影响很难预测。最终,缺失的环节是了解细胞HbF水平与血管闭塞可能性之间的定量关系。这将使我们能够预测新疗法的潜在疗效, 监测正在接受HbF诱导治疗(如羟基脲)的患者。在这些研究中,我们将量化血液HbF水平与血管闭塞风险之间的关系。我们的主要假设是HbF的治疗功效主要取决于HbF在红细胞(RBC)中的分布。如果所有RBC含有超过阈值百分比的HbF,则保护患者免于血管闭塞,但是将大部分HbF分离到仅少数细胞中并不能显著改善患者结果。我们提出使用流式细胞术直接检验该假设以量化单个RBC HbF分布(“HbF异质性”)。我们将患者血液的HbF异质性与血管闭塞的风险相关联。由于血管闭塞很难在体内研究或重现,我们开发了一个微流控平台来研究血管闭塞的体外。我们将使用该平台来量化血液样本中闭塞的可能性,并且我们将使用定量流式细胞术将该测量与从患者样本中测量的HbF异质性相关联。其结果将是一个临床检测,可用于监测患者对羟基脲的反应,并用于诱导HbF合成的新疗法的临床试验。此外,我们预计这些研究将阐明HbF是否是羟基脲的主要治疗机制。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Kevin Wood其他文献

David Kevin Wood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Kevin Wood', 18)}}的其他基金

Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
  • 批准号:
    10756268
  • 财政年份:
    2017
  • 资助金额:
    $ 19.21万
  • 项目类别:
Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
  • 批准号:
    10673595
  • 财政年份:
    2017
  • 资助金额:
    $ 19.21万
  • 项目类别:
Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
  • 批准号:
    10209656
  • 财政年份:
    2017
  • 资助金额:
    $ 19.21万
  • 项目类别:
Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
  • 批准号:
    10382453
  • 财政年份:
    2017
  • 资助金额:
    $ 19.21万
  • 项目类别:
A microfluidic platform to study sickle blood rheology
研究镰状血液流变学的微流控平台
  • 批准号:
    9684422
  • 财政年份:
    2017
  • 资助金额:
    $ 19.21万
  • 项目类别:
Carcinoma Cell Hyaluronan as a Therapeutic Target in Metastasis
癌细胞透明质酸作为转移治疗靶点
  • 批准号:
    9250092
  • 财政年份:
    2016
  • 资助金额:
    $ 19.21万
  • 项目类别:
A microfluidic platform to study sickle blood rheology
研究镰状血液流变学的微流控平台
  • 批准号:
    9324460
  • 财政年份:
    2016
  • 资助金额:
    $ 19.21万
  • 项目类别:
Carcinoma Cell Hyaluronan as a Therapeutic Target in Metastasis
癌细胞透明质酸作为转移治疗靶点
  • 批准号:
    9100026
  • 财政年份:
    2016
  • 资助金额:
    $ 19.21万
  • 项目类别:
Self-Organized Tissue Microvasculature
自组织组织微脉管系统
  • 批准号:
    7614893
  • 财政年份:
    2009
  • 资助金额:
    $ 19.21万
  • 项目类别:
Self-Organized Tissue Microvasculature
自组织组织微脉管系统
  • 批准号:
    7787518
  • 财政年份:
    2009
  • 资助金额:
    $ 19.21万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 19.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了